Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS …
…, O Molinier, R Corre, I Monnet, V Gounant… - 2015 - ascopubs.org
7500 Background: MPM median overall survival (OS) did not exceed 13 months with
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular endothelial …
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular endothelial …
[HTML][HTML] Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on …
…, B Milleron, A Cortot, N Girard, V Gounant… - Diagnostic and …, 2021 - Elsevier
Following the American National Lung Screening Trial results in 2011 a consortium of
French experts met to edit a statement. Recent results of other randomized trials gave the …
French experts met to edit a statement. Recent results of other randomized trials gave the …
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …
…, O Molinier, R Corre, I Monnet, V Gounant… - The Lancet, 2016 - thelancet.com
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
[HTML][HTML] A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with …
…, D Carmier, J Madelaine, J Otto, V Gounant… - Journal of Thoracic …, 2019 - Elsevier
Introduction This randomized phase II trial aimed at evaluating the engineered programmed
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
…, A Cazes, C Danel, B Abbar, J Pluvy, V Gounant… - Lung cancer, 2019 - Elsevier
Introduction Tumor mutational burden (TMB) correlates with response to immune checkpoint
inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that …
inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that …
[HTML][HTML] Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article
…, D Re, Z Adjtoutah, B Seitz-Polski, V Gounant… - European Journal of …, 2022 - Elsevier
Taking into account higher risk of severe coronavirus disease 2019 or death among patients
with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in …
with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in …
Six-month prognosis of patients with lung cancer admitted to the intensive care unit
…, A Parrot, A Lavole, PY Ancel, V Gounant… - Intensive care …, 2009 - Springer
Background Intensive care unit (ICU) admission of patients with lung cancer remains
debated because of the poor short-term prognosis. However, ICU admission of such patients …
debated because of the poor short-term prognosis. However, ICU admission of such patients …
[HTML][HTML] Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients …
V Gounant, VM Ferré, G Soussi, C Charpentier… - Journal of Thoracic …, 2022 - Elsevier
Introduction Coronavirus disease 2019 resulted in a 30% mortality rate in patients with
thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute …
thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute …
[HTML][HTML] Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma
…, I Monnet, J Mazières, F Barlesi, V Gounant… - Journal of Thoracic …, 2020 - Elsevier
Introduction Immune checkpoint inhibitors (ICIs) have improved cancer prognosis but have
not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype …
not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype …